Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2012, Article ID 324016, 5 pages
Clinical Study

Elevated Angiopoietin-1 Serum Levels in Patients with Alzheimer’s Disease

1Department of Psychiatry and Psychotherapy, University of Tübingen, 72076 Tuebingen, Germany
2DZNE, German Center for Neurodegenerative Diseases, 72076 Tübingen, Germany
3Section for Dementia Research, Department of Psychiatry and Psychotherapy, Hertie-Institute of Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany

Received 9 August 2012; Accepted 13 September 2012

Academic Editor: Michelle M. Mielke

Copyright © 2012 Brigitte Schreitmüller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Alzheimer's disease (AD) is the most common cause of dementia in the elderly. AD is characterized by the accumulation of amyloid plaques and neurofibrillary tangles and by massive neuronal loss in the brain. There is epidemiologic and pathologic evidence that AD is associated with vascular risk factors and vascular diseases, contributing to cerebral hypoperfusion with consecutive stimulation of angiogenesis and upregulation of proangiogenic factors such as Angiopoietin-1 (Ang-1). Methods. In the present study, we measured Ang-1 serum levels in 42 patients with AD, 20 patients with mild cognitive impairment (MCI), and in 40 healthy elderly controls by ELISA. Results. We found significantly increased Ang-1 serum levels in patients with AD compared to control subjects . There was no significant difference between MCI patients and healthy controls or between AD and MCI patients . The degree of cognitive impairment as measured by the mini-mental status examination (MMSE) score was significantly correlated with the Ang-1 serum levels in all patients and healthy controls. Conclusions. We found significantly increased Ang-1 serum levels in AD patients. We could also show an association between Ang-1 serum levels and the cognitive status in all patients and healthy controls. Thus, serum Ang-1 could be a potential candidate for a biomarker panel for AD diagnosis.